Donepezil Versus Non-drug Treatment in Alzheimer's Disease.

This French trial compares donepezil (a standard medication for Alzheimer's disease) against non-drug approaches (such as cognitive stimulation or other non-pharmacological interventions) in people with confirmed Alzheimer's disease, to see which approach better preserves thinking and quality of life. **You may be eligible if...** - You are 50 or older with a confirmed diagnosis of Alzheimer's disease - Your diagnosis is supported by specific biomarkers in spinal fluid (abnormal amyloid or tau levels) - Your cognitive score (MMSE) is 10 or higher - You are a native French speaker - If your MMSE is below 20, a family caregiver or household member is available to help with treatment compliance **You may NOT be eligible if...** - You have a different cause of dementia - You have already used Alzheimer's medication (like donepezil, memantine, rivastigmine) - You have heart rhythm problems (like bradycardia or heart block) or are on medications that can affect the QT interval - You have asthma, obstructive lung disease, epilepsy, or severe liver problems - You are currently participating in another interventional clinical trial Talk to your doctor to see if this trial is right for you.